NANO. Hvem vinner Roche eller Nordic Nanovecter .........


Results

212Pb-NNV003 displays a favorable toxicity profile after a single intravenous injection in tumor-free mice. No acute hematological toxicity was observed, and animals presented only a slight initial reduction in their platelets (PLT) counts which was fully recovered 4-weeks after injection. A single intravenous dose of 10, 15 or 20 μCi of 212Pb-NNV003 led to 70%, 90% and 100% of mice injected with MEC-2 cells being tumor free 20 weeks post cell injection. Control animals that received saline, cold antibody or 212Pb-cetuximab presented a median survival of 4.9, 5.4 and 9.3 weeks, respectively. A single intravenous dose of 2.5, 5 and 7.5 μCi 212Pb-NNV003 led to over 80% tumor-free mice injected with Daudi cells 15 weeks post cell injection. Control animals that received saline, cold antibody or 212Pb-cetuximab presented a median survival of 7, 7.8 and 7.7 weeks, respectively.

--------------------------------------------------------
Results

Inhibition of proliferation of the mouse lymphoma EL4-hCD20-Luc cell line was correlated with a dose-dependent increase in apoptosis after incubation with 212Pb-rituximab compared to 212Pb-irrelevant mAb or cold antibodies. Dose range finding (DRF) and acute toxicity studies were performed in order to determine the safety profile and safe administration doses. To evaluate in vivo efficacy of 212Pb-rituximab, 8-week-old C57BL/6JRj mice were injected intravenously with 25 x 103 EL4-hCD20-Luc cells and treated either 11 days or 20 to 30 days post cell injection with 277.5 kBq 212Pb-rituximab or relevant controls (including 277.5 kBq 212Pb-irrelevant mAb, cold rituximab and saline). Therapeutic efficacy was monitored by bioluminescence imaging (BLI) and overall survival. Mice treated with 212Pb-rituximab 20 to 30 days post cell injection (BLI-detectable tumors) exhibited marked tumor growth inhibition compared to controls, with a median survival of 28 days for 212Pb-rituximabtreated group instead of 9 to 13 days for control groups. Strongly improved median survival (above 105 days) was observed for mice treated with 212Pb-rituximab 11 days after cell injection, whereas median survival was reached 36.5 days post-treatment for 212Pb-irrelevant mAb, 64 days for cold rituximab and 27 days for saline control.

----------------------------------------------------------------

https://www.jmirs.org/action/doSearch?searchType=authorLookUp&author=Saidi,%20Amal&prod=HA


Hvorfor skriver du så mye rar tekst Korsar midt i beste arbeidstid.. det kan bli gigabytes til slutt på HO serveren uten særlig current eller historisk verdi..